Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
HCSG vs AMSF vs KNTK vs ABM vs CTAS
Revenue, margins, valuation, and 5-year total return — side by side.
Insurance - Specialty
Oil & Gas Midstream
Specialty Business Services
Specialty Business Services
HCSG vs AMSF vs KNTK vs ABM vs CTAS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Insurance - Specialty | Oil & Gas Midstream | Specialty Business Services | Specialty Business Services |
| Market Cap | $1.60B | $569M | $3.33B | $2.39B | $68.52B |
| Revenue (TTM) | $1.84B | $325M | $1.73B | $8.87B | $10.79B |
| Net Income (TTM) | $59M | $46M | $228M | $158M | $1.90B |
| Gross Margin | 13.3% | 47.6% | 24.8% | 11.5% | 50.2% |
| Operating Margin | 3.0% | 17.8% | 8.2% | 3.7% | 23.0% |
| Forward P/E | 20.8x | 14.4x | 42.4x | 10.3x | 34.8x |
| Total Debt | $25M | $491K | $3.87B | $1.69B | $2.65B |
| Cash & Equiv. | $161M | $62M | $4M | $104M | $264M |
HCSG vs AMSF vs KNTK vs ABM vs CTAS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Healthcare Services… (HCSG) | 100 | 93.3 | -6.7% |
| AMERISAFE, Inc. (AMSF) | 100 | 49.4 | -50.6% |
| Kinetik Holdings In… (KNTK) | 100 | 702.3 | +602.3% |
| ABM Industries Inco… (ABM) | 100 | 132.6 | +32.6% |
| Cintas Corporation (CTAS) | 100 | 274.3 | +174.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: HCSG vs AMSF vs KNTK vs ABM vs CTAS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
HCSG ranks third and is worth considering specifically for momentum.
- +55.8% vs AMSF's -29.2%
AMSF is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 0.23, Low D/E 0.2%, current ratio 0.32x
- Beta 0.23, yield 8.4%, current ratio 0.32x
- Beta 0.23 vs HCSG's 1.12, lower leverage
KNTK has the current edge in this matchup, primarily because of its strength in income & stability and growth exposure.
- Dividend streak 3 yrs, beta 0.60, yield 16.5%
- Rev growth 19.0%, EPS growth 157.8%, 3Y rev CAGR 13.3%
- 19.0% revenue growth vs AMSF's 2.6%
- 16.5% yield, 3-year raise streak, vs ABM's 2.6%, (1 stock pays no dividend)
ABM is the clearest fit if your priority is valuation efficiency.
- PEG 0.04 vs CTAS's 2.08
- Lower P/E (10.3x vs 34.8x), PEG 0.04 vs 2.08
CTAS is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- 6.9% 10Y total return vs ABM's 48.7%
- 17.6% margin vs ABM's 1.8%
- 18.7% ROA vs ABM's 3.0%, ROIC 25.8% vs 7.5%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 19.0% revenue growth vs AMSF's 2.6% | |
| Value | Lower P/E (10.3x vs 34.8x), PEG 0.04 vs 2.08 | |
| Quality / Margins | 17.6% margin vs ABM's 1.8% | |
| Stability / Safety | Beta 0.23 vs HCSG's 1.12, lower leverage | |
| Dividends | 16.5% yield, 3-year raise streak, vs ABM's 2.6%, (1 stock pays no dividend) | |
| Momentum (1Y) | +55.8% vs AMSF's -29.2% | |
| Efficiency (ROA) | 18.7% ROA vs ABM's 3.0%, ROIC 25.8% vs 7.5% |
HCSG vs AMSF vs KNTK vs ABM vs CTAS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
HCSG vs AMSF vs KNTK vs ABM vs CTAS — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
CTAS leads in 2 of 6 categories
ABM leads 1 • KNTK leads 1 • HCSG leads 0 • AMSF leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
CTAS leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CTAS is the larger business by revenue, generating $10.8B annually — 33.2x AMSF's $325M. CTAS is the more profitable business, keeping 17.6% of every revenue dollar as net income compared to ABM's 1.8%. On growth, AMSF holds the edge at +10.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1.8B | $325M | $1.7B | $8.9B | $10.8B |
| EBITDAEarnings before interest/tax | $72M | $58M | $534M | $431M | $2.9B |
| Net IncomeAfter-tax profit | $59M | $46M | $228M | $158M | $1.9B |
| Free Cash FlowCash after capex | $139M | $8M | $441M | $327M | $1.8B |
| Gross MarginGross profit ÷ Revenue | +13.3% | +47.6% | +24.8% | +11.5% | +50.2% |
| Operating MarginEBIT ÷ Revenue | +3.0% | +17.8% | +8.2% | +3.7% | +23.0% |
| Net MarginNet income ÷ Revenue | +3.2% | +14.3% | +13.2% | +1.8% | +17.6% |
| FCF MarginFCF ÷ Revenue | +7.6% | +2.5% | +25.5% | +3.7% | +16.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +6.6% | +10.3% | -7.5% | +6.1% | +9.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +175.0% | -8.5% | -2.4% | -7.2% | +11.0% |
Valuation Metrics
ABM leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 12.3x trailing earnings, AMSF trades at a 68% valuation discount to CTAS's 38.6x P/E. Adjusting for growth (PEG ratio), ABM offers better value at 0.05x vs CTAS's 2.31x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $1.6B | $569M | $3.3B | $2.4B | $68.5B |
| Enterprise ValueMkt cap + debt − cash | $1.5B | $508M | $7.2B | $4.0B | $70.9B |
| Trailing P/EPrice ÷ TTM EPS | 27.54x | 12.27x | 18.43x | 15.74x | 38.65x |
| Forward P/EPrice ÷ next-FY EPS est. | 20.83x | 14.42x | 42.44x | 10.30x | 34.75x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 0.05x | 2.31x |
| EV / EBITDAEnterprise value multiple | 22.38x | 8.53x | 13.14x | 9.23x | 24.85x |
| Price / SalesMarket cap ÷ Revenue | 0.87x | 1.80x | 1.89x | 0.27x | 6.63x |
| Price / BookPrice ÷ Book value/share | 3.19x | 2.30x | 1.04x | 1.43x | 14.89x |
| Price / FCFMarket cap ÷ FCF | 11.49x | 63.83x | 44.78x | 15.40x | 39.00x |
Profitability & Efficiency
CTAS leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
CTAS delivers a 42.6% return on equity — every $100 of shareholder capital generates $43 in annual profit, vs $9 for ABM. AMSF carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to KNTK's 1.32x. On the Piotroski fundamental quality scale (0–9), CTAS scores 9/9 vs KNTK's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +11.8% | +9.7% | +21.1% | +8.8% | +42.6% |
| ROA (TTM)Return on assets | +7.3% | +5.6% | +4.2% | +3.0% | +18.7% |
| ROICReturn on invested capital | +9.0% | +21.9% | +1.9% | +7.5% | +25.8% |
| ROCEReturn on capital employed | +7.7% | +16.8% | +2.5% | +8.2% | +29.8% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 7 | 4 | 6 | 9 |
| Debt / EquityFinancial leverage | 0.05x | 0.00x | 1.32x | 0.95x | 0.57x |
| Net DebtTotal debt minus cash | -$136M | -$61M | $3.9B | $1.6B | $2.4B |
| Cash & Equiv.Liquid assets | $161M | $62M | $4M | $104M | $264M |
| Total DebtShort + long-term debt | $25M | $491,000 | $3.9B | $1.7B | $2.7B |
| Interest CoverageEBIT ÷ Interest expense | 33.02x | — | 5.98x | 3.25x | 24.61x |
Total Returns (Dividends Reinvested)
KNTK leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CTAS five years ago would be worth $19,584 today (with dividends reinvested), compared to $7,888 for HCSG. Over the past 12 months, HCSG leads with a +55.8% total return vs AMSF's -29.2%. The 3-year compound annual growth rate (CAGR) favors KNTK at 24.7% vs AMSF's -9.1% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +28.6% | -18.3% | +37.4% | -3.1% | -7.8% |
| 1-Year ReturnPast 12 months | +55.8% | -29.2% | +28.0% | -16.0% | -20.1% |
| 3-Year ReturnCumulative with dividends | +48.6% | -24.8% | +93.9% | +3.4% | +51.7% |
| 5-Year ReturnCumulative with dividends | -21.1% | -18.9% | +93.1% | -14.1% | +95.8% |
| 10-Year ReturnCumulative with dividends | -26.8% | +31.8% | -33.5% | +48.7% | +685.0% |
| CAGR (3Y)Annualised 3-year return | +14.1% | -9.1% | +24.7% | +1.1% | +14.9% |
Risk & Volatility
Evenly matched — AMSF and KNTK each lead in 1 of 2 comparable metrics.
Risk & Volatility
AMSF is the less volatile stock with a 0.23 beta — it tends to amplify market swings less than HCSG's 1.12 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KNTK currently trades 94.8% from its 52-week high vs AMSF's 62.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.12x | 0.23x | 0.60x | 0.72x | 0.51x |
| 52-Week HighHighest price in past year | $24.39 | $48.54 | $51.11 | $52.94 | $229.24 |
| 52-Week LowLowest price in past year | $12.66 | $29.42 | $31.33 | $36.96 | $165.46 |
| % of 52W HighCurrent price vs 52-week peak | +91.5% | +62.4% | +94.8% | +77.0% | +74.2% |
| RSI (14)Momentum oscillator 0–100 | 61.8 | 34.2 | 51.3 | 54.8 | 37.7 |
| Avg Volume (50D)Average daily shares traded | 676K | 212K | 1.2M | 512K | 2.2M |
Analyst Outlook
Evenly matched — KNTK and ABM each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: HCSG as "Hold", AMSF as "Buy", KNTK as "Buy", ABM as "Hold", CTAS as "Hold". Consensus price targets imply 46.9% upside for AMSF (target: $45) vs -1.8% for KNTK (target: $48). For income investors, KNTK offers the higher dividend yield at 16.47% vs CTAS's 0.88%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Hold | Hold |
| Price TargetConsensus 12-month target | $24.50 | $44.50 | $47.57 | $50.00 | $223.40 |
| # AnalystsCovering analysts | 15 | 6 | 15 | 11 | 30 |
| Dividend YieldAnnual dividend ÷ price | — | +8.4% | +16.5% | +2.6% | +0.9% |
| Dividend StreakConsecutive years of raises | 20 | 0 | 3 | 36 | 3 |
| Dividend / ShareAnnual DPS | — | $2.55 | $7.98 | $1.05 | $1.49 |
| Buyback YieldShare repurchases ÷ mkt cap | +3.9% | +2.1% | +5.3% | +5.1% | +1.4% |
CTAS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ABM leads in 1 (Valuation Metrics). 2 tied.
HCSG vs AMSF vs KNTK vs ABM vs CTAS: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is HCSG or AMSF or KNTK or ABM or CTAS a better buy right now?
For growth investors, Kinetik Holdings Inc.
(KNTK) is the stronger pick with 19. 0% revenue growth year-over-year, versus 2. 6% for AMERISAFE, Inc. (AMSF). AMERISAFE, Inc. (AMSF) offers the better valuation at 12. 3x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate AMERISAFE, Inc. (AMSF) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — HCSG or AMSF or KNTK or ABM or CTAS?
On trailing P/E, AMERISAFE, Inc.
(AMSF) is the cheapest at 12. 3x versus Cintas Corporation at 38. 6x. On forward P/E, ABM Industries Incorporated is actually cheaper at 10. 3x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: ABM Industries Incorporated wins at 0. 04x versus Cintas Corporation's 2. 08x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — HCSG or AMSF or KNTK or ABM or CTAS?
Over the past 5 years, Cintas Corporation (CTAS) delivered a total return of +95.
8%, compared to -21. 1% for Healthcare Services Group, Inc. (HCSG). Over 10 years, the gap is even starker: CTAS returned +685. 0% versus KNTK's -33. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — HCSG or AMSF or KNTK or ABM or CTAS?
By beta (market sensitivity over 5 years), AMERISAFE, Inc.
(AMSF) is the lower-risk stock at 0. 23β versus Healthcare Services Group, Inc. 's 1. 12β — meaning HCSG is approximately 386% more volatile than AMSF relative to the S&P 500. On balance sheet safety, AMERISAFE, Inc. (AMSF) carries a lower debt/equity ratio of 0% versus 132% for Kinetik Holdings Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — HCSG or AMSF or KNTK or ABM or CTAS?
By revenue growth (latest reported year), Kinetik Holdings Inc.
(KNTK) is pulling ahead at 19. 0% versus 2. 6% for AMERISAFE, Inc. (AMSF). On earnings-per-share growth, the picture is similar: Kinetik Holdings Inc. grew EPS 157. 8% year-over-year, compared to -14. 5% for AMERISAFE, Inc.. Over a 3-year CAGR, KNTK leads at 13. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — HCSG or AMSF or KNTK or ABM or CTAS?
Cintas Corporation (CTAS) is the more profitable company, earning 17.
5% net margin versus 1. 9% for ABM Industries Incorporated — meaning it keeps 17. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CTAS leads at 22. 8% versus 2. 6% for HCSG. At the gross margin level — before operating expenses — CTAS leads at 50. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is HCSG or AMSF or KNTK or ABM or CTAS more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, ABM Industries Incorporated (ABM) is the more undervalued stock at a PEG of 0. 04x versus Cintas Corporation's 2. 08x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, ABM Industries Incorporated (ABM) trades at 10. 3x forward P/E versus 42. 4x for Kinetik Holdings Inc. — 32. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AMSF: 46. 9% to $44. 50.
08Which pays a better dividend — HCSG or AMSF or KNTK or ABM or CTAS?
In this comparison, KNTK (16.
5% yield), AMSF (8. 4% yield), ABM (2. 6% yield), CTAS (0. 9% yield) pay a dividend. HCSG does not pay a meaningful dividend and should not be held primarily for income.
09Is HCSG or AMSF or KNTK or ABM or CTAS better for a retirement portfolio?
For long-horizon retirement investors, Cintas Corporation (CTAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
51), 0. 9% yield, +685. 0% 10Y return). Both have compounded well over 10 years (CTAS: +685. 0%, HCSG: -26. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between HCSG and AMSF and KNTK and ABM and CTAS?
These companies operate in different sectors (HCSG (Healthcare) and AMSF (Financial Services) and KNTK (Energy) and ABM (Industrials) and CTAS (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: HCSG is a small-cap quality compounder stock; AMSF is a small-cap deep-value stock; KNTK is a small-cap high-growth stock; ABM is a small-cap deep-value stock; CTAS is a mid-cap quality compounder stock. AMSF, KNTK, ABM, CTAS pay a dividend while HCSG does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.